



UK and Ireland Neuroendocrine  
Tumour Society

NETS Basics Day  
13th September 2018

[netsbasicsday2018@outlook.com](mailto:netsbasicsday2018@outlook.com)

## FACULTY MEMBERS



### **Maralyn Druce**

Professor Maralyn Druce undertook undergraduate training at Christ's College, Cambridge University and completed her clinical training at UCLSM in 1994. She completed her higher medical training in Diabetes, Endocrinology and General Internal Medicine at the Hammersmith Hospital and Barts Hospital. She was awarded a Wellcome Trust clinical research training fellowship and obtained a PhD in physiology in Professor Steve Bloom's laboratory in Imperial College, focusing on gut hormones and their role in the peripheral and central control of energy homeostasis. She is now Professor of Endocrine Medicine at Barts and the London School of Medicine

and Consultant Physician and Endocrinologist at Barts Health NHS Trust. In addition to clinically-focussed research she has a strong interest in medical and endocrine education including novel methods in e-learning. She is the originator and Programme Director for the Postgraduate Diploma/MSc in Endocrinology and Diabetes Mellitus at Barts and the London School of Medicine as well as a further MSc in Clinical Endocrinology. She has previously sat on the programme organizing committee of the Society for Endocrinology and now Chairs the public engagement committee as well as chairing the education and training committee of UKINETS.



### **Andrea Frilling**

Professor Andrea Frilling, MD, PhD is affiliated as Professor of Surgery and Chair in Endocrine Surgery with the Imperial College London, UK. After her general surgical training she specialized in endocrine surgery, hepato-pancreato-biliary surgery and oncologic abdominal surgery. She has authored ~ 400 peer reviewed scientific papers and contributed to ~20 books on diverse subjects on endocrine and hepato-pancreato-biliary surgery. She is a Fellow of the Royal College of Surgeons, of the American College of Surgeon, the European Board of Endocrine Surgery and of the European Board of Hepato-Pancreato-Biliary-Surgery. Her focus at Imperial is on multimodal management of patients with neuroendocrine tumours

including a number of new biomarker-based approaches. In 2012 she organised an International Consensus Conference on Neuroendocrine Liver Metastases and developed guidelines including an

algorithm for their management published in Lancet Oncology. Together with an interdisciplinary group at the Imperial she successfully accomplished the ENETS certification programme for Centres of Excellence for Management of Gastro-Entero-Pancreatic Neuroendocrine Tumours with an emphasis on early diagnosis, multimodal treatment and translational research.



**Daniel Morganstein**

Dr Daniel Morganstein is a Consultant Endocrinologist at Chelsea and Westminster and Royal Marsden Hospitals, and Service Director for Endocrinology. He has interests in endocrine tumours and endocrine side effects of cancer treatments. Working closely with oncology colleagues he works in specialist neuroendocrine and medullary thyroid cancer clinics. He also continues to look after diabetes and a commitment to acute medicine.



**Alia Munir**

Dr Alia Munir trained in Medicine at the University of Wales College of Medicine and began her basic clinical training in Cardiff and South Wales. She then began her specialist training in Guy's and St Thomas' London and later completed her higher medical training in Diabetes, Endocrinology and General Internal Medicine at Sheffield Teaching Hospitals (STH). She was awarded The Society for Endocrinology Clinical Trust Research Fellowship and obtained a PhD in Professor Newell-Prices' laboratory, focussing on RNA interference as a Therapy for Cushing's Disease, leading to a patent and orphan drug designation. She was appointed Consultant in Diabetes and Endocrinology in Pinderfields Hospital, Mid Yorkshire 2011-2015. She

was also appointed Consultant Endocrinologist in STH and coordinated Sheffield's successful European Neuroendocrine Tumour Society Centre of Excellence award in 2016. She is currently lead in a joint working partnership with Novartis and part of the 4<sup>th</sup> Wave Education programme with Ipsen.



**Mark Pritchard**

Prof Pritchard studied Medicine at Manchester University (BSc (1st class Hons) in Medical Biochemistry, 1988; MB.ChB. (with Hons), 1991). After junior hospital posts (MRCP(UK) 1994), he returned to the University of Manchester to train in Gastroenterology and performed research on the genetic regulation of apoptosis in the GI tract (Digestive Disorders Foundation and MRC Clinical Research Training Fellowships leading to PhD, 1999). In 2000 he moved to the University of Liverpool as a clinical lecturer to complete clinical training in Gastroenterology. Following this he was awarded an Advanced Fellowship for Clinicians from the Wellcome Trust (2002-6) to study

the importance of *Helicobacter pylori*-induced apoptosis during gastric tumour development. He was awarded the ASNEMGE Rising Star award in 2007 and the Sir Francis Avery Jones Research Medal of the British Society of Gastroenterology in 2008. He was appointed Clinical Senior Lecturer

at the University of Liverpool in 2006, Professor in 2009, Head of the Department of Gastroenterology in 2010 and Head of the Department of Cellular and Molecular Physiology in 2016. His current research focuses upon host factors which influence the development of gastrointestinal cancers and neuroendocrine tumours, in particular the importance of apoptosis, NF- $\kappa$ B signalling and the gastrin family of peptides. He is also an honorary Consultant Gastroenterologist at Royal Liverpool University Hospital, where he is the clinical lead of the Liverpool European Neuroendocrine Tumour Society (ENETS) Centre of Excellence and is involved in the clinical and endoscopic management of patients with gastroenteropancreatic neuroendocrine tumours. He also currently chairs the Gastroduodenal Section committee of the British Society of Gastroenterology.



**Jon Wadsley**

Dr Jon Wadsley is a Consultant Clinical Oncologist at Weston Park Hospital, Sheffield. His main clinical areas of interest are in thyroid cancer, neuroendocrine tumours, upper gastrointestinal and hepatobiliary cancers. He has a particular interest in molecular radiotherapy treatments for these tumours. He is a member of the NCRI Thyroid Clinical Studies Group, the NCRI Neuroendocrine Tumour Clinical Studies Group and is Clinical Lead for Division 1 of the Yorkshire and Humber Clinical Research Network.

## Contributing Faculty



**Judith Cave**

Dr Cave trained at UCLH (University College London Hospitals) and the Royal Free Hospital, and been a consultant in Southampton since January 2009. She has expertise in the management of lung and neuroendocrine tumours (NETs), and is the lung cancer multidisciplinary team chair. She is the research lead for NETs and is proud to have been part of the successful bid for Wessex to become a European Centre of Excellence for NETs.

Dr Cave has an MD in medical education and is involved in undergraduate and postgraduate education. She is a divisional director of medical education at University Hospital Southampton NHS FT.